Loading organizations...
Key people at Perclose, Inc..
Perclose, Inc. developed advanced suture-mediated closure devices for vascular access sites. Its core product line, spearheaded by the Perclose Closer Device, provided a percutaneous method for sealing arterial and venous punctures following interventional procedures. The technology focused on delivering sutures to close the vessel wall from within, offering a less invasive alternative to manual compression or surgical repair.
The company was founded in 1992, with D. Bruce Modesitt recognized as the primary inventor and designer of the foundational Perclose Closer Device. Modesitt's insight centered on improving patient outcomes and procedural efficiency through a novel mechanical approach to hemostasis. Hank Plain later served as Chief Executive Officer, guiding the company through its product development and market expansion phase.
Perclose's products served interventional cardiologists and radiologists seeking more efficient and patient-friendly solutions for post-procedure vascular closure. The company's vision was to enhance safety and reduce recovery times for patients undergoing catheter-based diagnostic and therapeutic procedures, aiming to become the standard of care for femoral access site management.
Key people at Perclose, Inc..
Perclose, Inc. was a medical device company that developed suture-mediated arterial closure devices to seal femoral artery access sites after diagnostic or interventional catheterization procedures. It served interventional cardiologists, vascular surgeons, and cath lab teams, solving the problem of achieving rapid, secure hemostasis without manual compression, which reduces time to ambulation, discharge, and complications like bleeding or pseudoaneurysms.[2][3][4][5] Acquired by Abbott Laboratories in a $680 million stock-for-stock deal around 2001 (expected year-end completion), Perclose's technology evolved into flagship products like Perclose ProGlide and the next-generation Perclose ProStyle, now part of Abbott Vascular's portfolio with broad indications for 5-21F arterial and 5-24F venous sheaths.[2][3][4][5]
Perclose, Inc. was founded in Redwood City, California, as a pioneer in the emerging arterial closure device market, which was less than five years old at the time of its acquisition and growing at over 40% annually amid rising catheterization procedures (over seven million worldwide, though under 20% used closure devices).[2] The company gained early traction with suture-based systems like the Techstar XL, though it faced a voluntary recall in 2001 due to a manufacturing issue with needle deployment, which was quickly resolved.[2] Abbott Laboratories acquired Perclose to bolster its cardiovascular portfolio, integrating and advancing the technology into systems like ProGlide and ProStyle.[2][3][4]
Perclose's technology stood out in vascular closure through suture-mediated closure and repair (SMCR), paralleling surgical gold standards while enabling percutaneous use:
(Note: A conflicting source lists Perclose in custom software/IT services with 500-999 employees and $250-500M revenue, but this appears erroneous given consistent medtech evidence.[1][2][3][4][5])
Perclose rode the explosive growth of minimally invasive cardiovascular interventions, where closure devices addressed a key bottleneck in over seven million annual catheterizations by enabling faster recovery and repeat access.[2] Timing was ideal as the market surged >40% CAGR in the early 2000s, driven by rising procedures for diagnostics and stents.[2] Abbott's acquisition amplified its influence, embedding Perclose tech into global standards like ProGlide/ProStyle, which promote vessel healing and reduce complications amid trends toward larger sheaths and venous closures.[3][4][5] This shaped the ecosystem by setting benchmarks for suture-based systems over collagen plugs, influencing competitors and expanding cath lab efficiency.
Perclose's legacy endures through Abbott's ongoing innovations like ProStyle, with enhancements for challenging anatomy signaling adaptation to complex procedures (e.g., TAVR, EVAR).[3] Rising minimally invasive interventions and venous access needs will drive demand, potentially expanding indications or AI-guided deployment. As cath volumes grow with aging populations, Perclose tech's role in enabling same-day discharges could solidify Abbott's dominance, evolving from acquisition target to ecosystem cornerstone.[2][3][4][5]
